Joint Clinical Trials Office

You are here

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

Clinical Trial Details

This study will enroll 25 metastatic prostate cancer patients at the Deparment of Radiation Oncology at Weill Cornell Medical Center. It is an outpatient study that will utilize the ViewRay MRIdian Linac system for treatment. ViewRay is a radiation delivery machine that has real-time MRI imaging, which allows clinicians to better see and target tumors within the prostate, enabling them to precisely and accurately target areas within the prostate to a higher radiation dose.

ViewRay also offers the ability to provide "live" image guidance during treatment. This allows clinicians to see the prostate and surrounding organs in better detail, and helps to deliver precise, higher radiation to nodules within the prostate. There are many ways to treat the prostate, but stereotactic body radiation therapy (SBRT) is often chosen because it can be delivered within 5 treatments.

By selectively treating tumors within the prostate to a higher dose, this study hopes to improve tumor control without increasing side effects that can occur when the entire prostate is treated to a high dose.
Key Eligibility: 

Inclusion Criteria

  • Biopsy-proven diagnosis of prostate adenocarcinoma 
  • Age 18 or older
  • Must have metastatic prostate cancer proven on biopsy or imaging 

Exclusion Criteria

  • History of prior pelvic radiation (external beam or brachytherapy) 
  • Inability to undergo MRI 
  • AUA score greater than 20 
  • For patients on systemic therapy, enrollment must be within six months of start of therapy unless exception is made by protocol PIs.

Detailed eligibility will be reviewed when you contact the study team. 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Sharanya Chandrasekhar
(646) 962-2196
shc2043@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1904020263

ClinicalTrials.gov:

NCT04220983

Status

Open to Enrollment

Age Group

Adult

Sponsor